Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...

Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...

For nearly 20 years, mesothelioma treatment options were limited to a single regimen: pemetrexed with a platinum agent. Now, there are 3 systemic treatment options available. In this video, Hedy Lee ...

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

Updated ASCO guidelines for pleural mesothelioma refine surgery use, recommend immunotherapy, genetic testing, and improve ...

Adding cabozantinib to first-line treatment with nivolumab and ipilimumab improved PFS — but not OS — in patients with RCC.

The FDA is conducting a priority review of nivolumab plus ipilimumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer. The FDA has accepted a ...

A team has developed scSPOT, a new technique that reveals how immune cells called Tregs simultaneously control the immune system. The team identified key immune cells controlled by Tregs and found ...

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for an Opdivo (nivolumab) and Yervoy (ipilimumab) combo as a first ...

A Prescription Drug User Fee Act target date of June 23, 2025, has been set for the application. The US Food and Drug Administration (FDA) has accepted the supplemental biologics license ...

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially serious toxicities that should be closely monitored. According to an ...

HIF2α gene expression and clinical outcomes in patients with clear cell renal cell carcinoma with and without sarcomatoid differentiation. Efficacy and safety of fruquintinib combined with serplulimab ...